Photobiomodulation for Alzheimer’s disease : translating basic research to clinical application by Enengla, Joachim et al.
Journal of Alzheimer’s Disease 75 (2020) 1073–1082
DOI 10.3233/JAD-191210
IOS Press
1073
Review
Photobiomodulation for Alzheimer’s
Disease: Translating Basic Research
to Clinical Application
Joachim Enengla, Michael R. Hamblinb,c,d and Peter Dungele,∗
aUAS Technikum Wien, Vienna, Austria
bWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA
cDepartment of Dermatology, Harvard Medical School, Boston, MA, USA
dLaser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein, South Africa
eLudwig Boltzmann Institute for Experimental and Clinical Traumatology, Vienna, Austria
Handling Associate Editor: Jessica Peter
Accepted 27 March 2020
Abstract. One of the challenges in translating new therapeutic approaches to the patient bedside lies in bridging the gap
between scientists who are conducting basic laboratory research and medical practitioners who are not exposed to highly
specialized journals. This review covers the literature on photobiomodulation therapy as a novel approach to prevent and
treat Alzheimer’s disease, aiming to bridge that gap by gathering together the terms and technical specifications into a single
concise suggestion for a treatment protocol. In light of the predicted doubling in the number of people affected by dementia
and Alzheimer’s disease within the next 30 years, a treatment option which has already shown promising results in cell
culture studies and animal models, and whose safety has already been proven in humans, must not be left in the dark. This
review covers the mechanistic action of photobiomodulation therapy against Alzheimer’s disease at a cellular level. Safe
and effective doses have been found in animal models, and the first human case studies have provided reasons to undertake
large-scale clinical trials. A brief discussion of the minimally effective and maximum tolerated dose concludes this review,
and provides the basis for a successful translation from bench to bedside.
Keywords: Alzheimer’s disease, cognitive dysfunction, dementia, low-level light therapy, neuroimmunomodulation, photo-
biomodulation therapy
INTRODUCTION
According to the American Alzheimer’s Associa-
tion, 11% of Americans (aged 65 and older) suffer
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from Alzheimer’s disease (AD) [1]. There is a simi-
lar situation in Austria, where about 100,000 people
(6.4% of Austrians aged 65 and older) suffer from
AD, and this is predicted to reach 230,000 by the
year 2050 [2]. This rise in numbers affected is
mainly caused by the overall aging of the population
with increased life expectancy, and the generation
called “Baby-Boomers” (people born in the 1950s
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and 1960s) reaching the relevant age [2]. Because
it affects such a large number of individuals, AD is
becoming a major challenge to the health care system.
About one billion Euro per year is spent on AD-care
in Austria alone [2, 3], three quarters of which is non-
medical expense related to personal assistance in the
activities of daily life. Aside from being costly to
patients and the state, AD also claims its toll on the
quality of life of caregivers. Compared to people who
are not affected by AD directly or indirectly, those
who care for AD patients have shown weaker immune
function, more pro-inflammatory proteins, as well as
significantly shorter telomeres [4]. As yet there is no
established medical treatment that can cure, prevent,
or completely halt the progression of AD. The lack
of treatment options is aggravated by the paucity of
reliable diagnostic tools that could detect the pres-
ence of disease before the onset of symptoms. The
pre-symptomatic period of AD may last for decades,
but once symptoms start to appear, there is only a
short therapeutic window before neurodegeneration
renders the affected person completely dependent on
external care.
The key to a cure of AD may still lay in the dark, but
there is an increasing amount of research being done
that suggests that “literal enlightenment” might pave
the way as a therapy against AD. Starting off by sim-
ply searching for “low level light therapy Alzheimer’s
disease” in the PubMed database of the National
Center for Biotechnology Information, it quickly
becomes obvious that there are many different names
for treatments utilizing light. While Kendric C. Smith
suggested to use the “simple and correct term, pho-
totherapy” [5], the scientific consensus has recently
introduced the term “photobiomodulation therapy”
for what used to be called low level laser/light ther-
apy [6, 7]. As the literature also shows, it is possible to
apply photobiomodulation to the brain transcranially,
for which even more different terms and abbrevi-
ations exist. Figure 1 provides an overview of the
multiple historic terms describing the same technique
that is now grouped under the term photobiomod-
ulation (PBM). Albeit the terminology might be
outdated, limiting a literature search to the MeSH
terms “Photobiomodulation” and “Alzheimer’s dis-
ease” falls a long way short of what can be found
when performing a query containing a combination
of all search terms from Fig. 1 and identifiers for AD
and dementia. The necessity of including outdated
and confusing terminology to find more articles con-
cerning PBM for AD in humans [8–13] has motivated
us to present this compelling treatment approach
against neurodegeneration in a structured and concise
matter.
LITERATURE SUMMARY
PBM is defined as the use of monochromatic or
quasi-monochromatic light from a low power laser or
light emitting diode (LED) source to modify or mod-
ulate biological functions. This modulation effect is
based on the presence of chromophores in cells and
tissues. These chromophores are molecules capable
of absorbing light, whose excitation can influence
further downstream molecules and biochemical path-
ways with the potential to exert a therapeutic effect
[14]. The optical power output of any light source
used for PBM is measured in Watts (W), in combina-
tion with a defined working distance this translates
to an optical power density measured in W/m2 at
the point of application. Since only lower power
densities are generally used in PBM, the units are
usually converted and directly expressed as mW/cm2
(1 W/m2 corresponds to 0.1 mW/cm2). The total dose
of optical energy received during a PBM treatment is
measured in Joules (J), i.e., optical power in Watts
multiplied by treatment time in seconds. In the lit-
erature reviewed for this article, the dose (energy
density) is often stated over the treatment area, i.e.,
as J/cm2.
One proposed target receptor molecule in PBM
(widely discussed in the literature) is Complex IV
(cytochrome c oxidase, CCO) of the mitochon-
drial respiratory chain. Photons are absorbed by
CCO and increase the enzyme activity and thus the
activity of the mitochondrial respiratory chain. Fol-
lowing this primary photon absorption event, the
increased mitochondrial activity triggers secondary
effects by activating pathways, which are involved
in energy metabolism, cell homeostasis, and cell
survival signaling. The secondary effects of PBM
then amplify the primary effects by upregulating
the levels of CCO protein itself and thus creating
more of the target chromophore for additional PBM
[11, 15].
As a treatment for neck pain, arthritis, and for
carpal tunnel syndrome, PBM was shown to have an
efficacy beyond a mere placebo effect [16], which led
to the first low-level light therapy devices for pain
relief being approved as medical devices by the U.S.
Food and Drug Administration [17]. The power den-
sity delivered in PBM is generally too low to cause
any concerns about tissue heating or thermal damage
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Fig. 1. Many terms for the use of light in medical applications can be grouped under the umbrella term of photobiomodulation (PBM). When
used against Alzheimer’s disease, photobiomodulation utilizes comparatively low power (low level) near-infrared laser or LED light which
can be applied in a transcranial manner for photo-neuro-modulation.
[18]. PBM has very few reported side-effects, and in
animal studies it appears to be safe even when applied
long term [19]. While the long-term data from ani-
mal studies can be extrapolated to human lifespans,
it should be noted that the effects of long-term use of
PBM have yet to be studied in human subjects.
Interest in the use of PBM for neuro-rehabilitation
is growing, and it has already shown potential in
treating traumatic brain injury, stroke, psychiatric dis-
orders, as well as neurodegenerative disease both in
animal models and in some clinical trials and case
studies in humans [20–22].
Transcranial photobiomodulation with red to
near infra-red light
To make PBM work on the brain, one can take
advantage of the optical tissue window which allows
wavelengths of light between approximately 650 nm
and 1200 nm to travel through skin and skull, i.e.,
transcranially. The boundaries of the optical tis-
sue window are defined by the strong absorption
of hemoglobin and water. The penetration depth
of wavelengths within those boundaries was mea-
sured for example by Tedford et al., who achieved
a maximal penetration depth at a wavelength of
808 nm [23, 24]. Wang and Li evaluated this fur-
ther and confirmed 810 nm as well as 660 nm to
be the best suitable wavelengths for transcranial
PBM [25].
In order to deliver light to the brain even deeper,
without having to open the skull, Bungart et al.
suggest the use of nanoparticles as an alternative
light source for PBM [26]. These nanoparticles,
termed ‘Bioluminescence Resonance Energy Trans-
fer to Quantum Dots’ (BRET-Qdots), emit light in
the near-infrared (NIR) wavelength range when their
luciferase enzyme is activated with coelenterazine-h
substrate. The reported downside to a nanoparticle
treatment is concerns about the toxicity of the heavy
metal content of the BRET-Qdots, which are yet
to be fully investigated. Considering that blood has
been observed to contain circulating cell-free respi-
ratory competent mitochondria [27], and PBM also
increases regional blood flow [8, 28, 29], a secondary
mechanism might allow the transportation of the ben-
eficial effects of PBM beyond the limits of direct light
penetration.
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Molecular mechanisms of photobiomodulation
and their implications for Alzheimer’s disease
The impact of PBM on cell culture and animal
models of AD has been extensively studied. A sum-
mary of the progress in each stage of development
from basic research to preclinical and clinical Phase
I and II trials is presented to form the basis for a
treatment protocol.
PBM and AD in vitro
Sommer et al. reported that PBM reduced amyloid-
 (A25–35) aggregates in human neuroblastoma
cells [30] and Yang et al. observed a reduction
in A-induced oxidative stress and inflammatory
responses in rat primary cortical astrocytes [31].
Looking further at the implications of PBM on neuro-
inflammatory pathways, Song et al. observed the
effects of He-Ne laser light (632.8 nm) at doses from
3 J/cm2 to 50 J/cm2 on central nervous system res-
ident macrophages (microglia) in human neuronal
cells [32], and concluded that 20 J/cm2 at inter-
vals of 24 h was the optimal dose to attenuate cell
death by reducing microglia-mediated neurotoxic-
ity via the tyrosine-protein kinase Src/Syk signaling
pathway [30].
Liang et al. and Zhang et al. both examined the
pathways leading to cell apoptosis following the addi-
tion of aggregated A25–35 to neuronal-differentiated
rat pheochromocytoma (PC12) cells, and observed
that treatment with low power light using a He-Ne
laser at 623.8 nm demonstrated a positive effect of
PBM [33–35]. Zhang et al. specifically reported that
protein kinase B was activated by PBM at a dose
of 2 J/cm2, which in turn promoted a series of anti-
apoptotic effects such as inhibiting the translocation
of the pro-apoptotic Yes-associated protein from the
cytoplasm to the nucleus [35]. PBM using a He-
Ne laser also appeared to activate protein kinase C,
thereby affecting downstream apoptotic proteins in
a dose-dependent manner [34]. Irradiation for 5 to
20 min with a power density of 0.52 mW/cm2, cor-
responding to a delivered dose of 0.156 J/cm2 to
0.624 J/cm2, decreased levels of the pro-apoptotic
Bax and either increased or did not affect levels of the
anti-apoptotic Bcl-XL as compared to control cells
treated with the toxic amyloid peptide A25–35. This
effect was reversed when an irradiation time of 40 min
with 0.52 mW/cm2 was reached, corresponding to a
delivered dose of 1.248 J/cm2, which illustrates the
biphasic dose dependence of PBM when used to
counteract A-induced cell apoptosis. The reports
Fig. 2. Summary of the signaling pathways influenced by pho-
tobiomodulation, which appear to inhibit A-induced nerve cell
apoptosis while simultaneously promoting nerve cell survival. For
full names of enzymes/proteins see list of abbreviations at the end
of the manuscript.
from Liang et al. who used a 632.8 nm He-Ne laser
at a dose of 2 J/cm2 on neuronal PC12 cells treated
with A25–35 showed that PBM had a pro-survival
effect by acting on the Akt/GSK3/-catenin path-
way [33]. Building on the hypothesis that A-induced
neurotoxicity and dendrite atrophy may be a conse-
quence of a deficiency of brain-derived neurotropic
factor (BDNF), Meng et al. reported that extracellular
signal–regulated kinase could be activated with a He-
Ne laser at doses from 0.5 J/cm2 to 4 J/cm2 applied to
A25–35-treated human neuronal cells, which upreg-
ulated BDNF in a CREB-dependent manner [36]. A
summary of the cell signaling effects of PBM in vitro
is shown in Fig. 2.
PBM and AD in vivo
Using a mouse model of AD, Farfara et al. and
Oron et al. were able to ameliorate disease progres-
sion by stimulating the proliferation of mesenchymal
stem cells (MSCs) with PBM [37, 38]. Weekly treat-
ments using PBM at a dose of 1 J/cm2 applied to
the bone marrow of AD-mice increased the ability of
MSCs to phagocytose A-proteins within the brain,
which led to improved cognitive function and spatial
learning after a total treatment duration of 2 months,
compared to a sham-treated control group. This is
an interesting observation, albeit outside the scope of
this review, since it refers not to the effect of PBM
on brain cells directly, but rather on secondary effects
through stimulation of MSCs.
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Purushothuman et al. used two transgenic mouse
models of AD, engineered to either develop neurofib-
rillary tangles or A plaques, and treated them for a
total of 20 times over the course of four weeks with
LED light at 670 nm, delivering a dose of 4 J/cm2
per treatment, and provided histochemical evidence
of a beneficial effect [39]. Neurofibrillary tangles,
hyperphosphorylated tau protein, and oxidative stress
markers were reduced to near wild-type levels, and
the PBM treatment also reduced the number and size
of the A plaques.
De Taboada et al. used a GaAIAs diode laser with
a wavelength of 808 nm ± 10 nm to deliver increas-
ing doses, ranging from 4.8 J/cm2 (1.2 J/cm2 at the
cortical surface) to 48 J/cm2 (12 J/cm2 at cortical sur-
face), three times per week for a total duration of
six months to transgenic mice engineered to develop
A plaques [40]. Their results showed an attenua-
tion of amyloid development and improved cognitive
function, leading to the conclusion that early and reg-
ular administration of PBM has the potential to halt
progression from mild cognitive impairment to AD.
Applications of transcranial photobiomodulation
to human subjects supporting its therapeutic
value for neurological use
In an opinion article by Gonzalez-Lima and
Barrett [18], the authors summarized how the devel-
opment of PBM has evolved over the last 40
years to a point where it is beginning to be used
for cognitive-enhancement applications. They con-
ducted a placebo-controlled study focusing on the
beneficial cognitive and emotional effects in healthy
human volunteers of either sex, age ranging from
18 to 35 years to test this hypothesis. Two weeks
after a single therapy session a significant improve-
ment in cognitive tests was observed [41]. These
beneficial effects were reflected in improvements in
reaction time in a sustained-attention psychomotor
vigilance task, in a delayed match-to-sample memory
task, and a self-reported Positive and Negative Affect
Schedule. Blanco et al. then used the Wisconsin Card
Sorting Task in a placebo controlled study on healthy
human participants, directly after receiving the PBM
treatment to assess the effects of transcranial infrared
laser stimulation on executive function [42]. Here,
laser light at a wavelength of 1064 nm and power
density of 250 mW/cm2 was applied to two locations
on the right portion of the forehead for a total of
4 min per site. The total supplied dose in this study
again corresponded to those stated above, 60 J/cm2
per site, and the treatment group performed signifi-
cantly better than the control group in the Wisconsin
Card Sorting Task.
Schiffer et al. reported the beneficial effects of
transcranial PBM on anxiety and depression in a
study in which PBM was applied using an LED array
with peak wavelength at 810 nm and an energy den-
sity of 250 mW/cm2 [43]. They calculated that from
the supplied dose of 60 J/cm2 at the scalp, an effective
2.1 J/cm2 (3.7%) reached the dura of the brain. Pos-
itive effects of a single treatment session (compared
to pre-treatment levels) were observed two weeks
after PBM, which waned by the time of a further
assessment after four weeks.
Chan et al. observed improved frontal cognitive
function in older human volunteers (≥60 years) after
a single session of PBM [44]. The device used in
their study consisted of three LED cluster heads with
a mix of 633 nm and 870 nm diodes and a power den-
sity of 44.4 mW/cm2. Applied for 7.5 min, the devices
delivered a dose of 20 J/cm2 at the scalp and study par-
ticipants showed improved reaction time, measured
by a modified Eriksen flanker test, and improved men-
tal flexibility, measured by a category fluency test.
Improved cognitive function was also observed by
Naeser et al. in case studies where transcranial PBM
was used after traumatic brain injury [45, 46], and
after left hemisphere stroke, in patients with chronic
aphasia [47]. The devices in these studies by Naeser
et al. consisted of LED cluster heads, with a mix of
633 nm and 870 nm diodes similar to those used by
Chan et al., but with a power density of 22.2 mW/cm2.
Each treatment site on the scalp received a dose
primarily at 13 or 26 J/cm2 at each LED cluster place-
ment on the head during a treatment series lasting
six weeks (3× per week). The post-PBM testing for
the traumatic brain injury participants performed at
1 week, 1 month, and 2 months after the final, 18th
treatment with the LED cluster heads, showed signifi-
cant improvements in cognitive function, as measured
by the Stroop Test (executive function), and the Cali-
fornia Verbal Learning Test-II (verbal memory). The
post-PBM testing for the chronic stroke patients with
aphasia showed significant improvements in naming
when optimal LED cluster scalp placements (ipsile-
sional, left hemisphere, and two midline nodes of the
default mode network) and 26 J/cm2 were used.
As stated by Hashmi et al. in their article about the
role of PBM in neurorehabilitation [20], transcranial
PBM with low level red to NIR light had already been
used on human subjects with moderate AD before the
year 2010, although no peer reviewed publications
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existed as of then. This is slowly changing, with new
devices being developed and more individuals being
treated in pilot trials, confirming improvements in the
Alzheimer’s Disease Assessment Scale-cognitive and
enhanced Neuropsychiatric Inventory scores, as well
as an increase in regional cerebral blood flow and
increased connectivity of the default mode network
[29,48–53].
Minimum effective and maximum tolerated dose
When red to NIR monochromatic or quasi-
monochromatic light is absorbed by cytochrome
oxidase in neuronal mitochondria, the photons
increase the proton gradient of the mitochondrial
membrane and thus modulate ATP production. The
effective dose of PBM appears to follow the principle
of hormesis, meaning that low doses are stimulatory
while higher doses are less effective or even coun-
terproductive. The minimum effective and maximum
tolerated dose has been experimentally evaluated in
vitro and in vivo, the translation of these results to
transcranial application in humans is supported by
results from studies on tissue optical properties and
the penetration depth of red and NIR light in the
intermediate tissue overlying the brain.
Hormesis
The hormetic effect (or biphasic dose response) of
PBM was shown by Gonzalez-Lima and Barrett in a
study in rats, where 660 nm LED arrays with a power
density of 9 mW/cm2 showed the highest increase in
cytochrome oxidase activity at a dose of 10.9 J/cm2
(13.6% increase), slightly less at the higher dose of
21.6 J/cm2 (10.3% increased activity) and finally only
a non-significant increase (3%) at the highest dose
of 32.9 J/cm2 [18]. Using fluorescence-quenching to
measure oxygen concentration in the cortex allowing
estimates of neuronal oxygen consumption, Rojas et
al. reported a 5% increase in oxygen consumption
at 1 J/cm2 and a 16% increase at a dose of 5 J/cm2
when using PBM with 660 nm and a power density
of 9 mW/cm2 in rats [54].
Pulsing
Aside from wavelength and dose, the question of
whether a light source used for PBM should emit con-
tinuous wave or pulsed light, has led to investigations
of different pulse structures. Upon reviewing nine
studies which directly compared continuous wave
with pulse wave light, Hashmi et al. summarized that
six of these nine studies found pulsed light to be more
effective than continuous wave [55]. In an effort to
find optimal parameters for PBM in wound healing,
Barolet et al. studied various pulsing patterns and also
found pulsing to be more beneficial in comparison to
continuous wave illumination [56]. For PBM to the
brain, finding the optimal pulsing parameters bene-
fits from the fact that neural oscillations measured by
electroencephalography recordings have been linked
to different mental processes. Memory processes are
most closely related to oscillations with theta and
gamma frequencies (6 Hz and 40 Hz, respectively),
while attention seems closely associated with alpha
and gamma oscillations (10 Hz and 40 Hz, respec-
tively) [57]. So, in an analogous manner to how the
brain can be modulated with acoustical frequencies
(10 Hz or 40 Hz) using binaural auditory beats [58],
pulsed light at alpha or gamma frequencies elicited a
positive effect on the brain in mouse models of AD
[59, 60].
Transmission
Tedford et al. quantitatively analyzed the amount
of light that reached the brain using human cadaver
heads, which they sectioned in such way that all of
the intermediate tissues were kept intact and the opti-
cal energy was measured “in situ” within the brain
[23]. Results showed an exponential increase in flu-
ence rate with a linear decrease in distance between
measurement probe and light source. An absorption
coefficient for each of the measured wavelengths was
also provided which could be used to calculate the
dose supplied to any point inside the brain using
Equation (1):
F (x)
[
mW
cm2
]
= F0
[
mW
cm2
]
· e−μ
[
cm−1
]
× [cm] (1)
with F(x) being the radiant intensity delivered to the
point inside the brain in mW/cm2 per 1 mW/cm2
delivered to the surface of the scalp (F0), and x being
the distance between the surface of the scalp and the
point of interest inside the brain. The value for is the
absorption coefficient of the tissue at each supplied
wavelength; at 660 nm it is 3.3504 cm–1, at 808 nm
it is 2.5541 cm–1, and at 940 nm it is 3.3922 cm–1.
Lychagov et al. studied the NIR transmittance of
the human skull and demonstrated that 0.5% to 5% of
the emitted light from a 1 W laser with a wavelength
of 810 nm was transmitted transcranially, confirming
the exponential relationship between the thickness of
skin and bone and light transmission in the NIR-range
[61].
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Table 1
Excerpted from the results published in [62]
Control Beneath skin and skull
(Air only, at a temporal frontal occipital
distance of 10 mm)
830 nm 33.3 mW/cm2 0.3 mW/cm2 0.71 mW/cm2 3.9 mW/cm2
100% 0.9% 2.1% 11.7%
633 nm 67.5 mW/cm2 <0.001 mW/cm2 0.37 mW/cm2 0.44 mW/cm2
100% 0.0% 0.5% 0.7%
Table 2
Excerpted from the results published in [63]
Wavelength 632.8 nm 675 nm 780 nm 835 nm
Penetration Depth
[mm ± standard error]
n = 10
0.92 ± 0.08 1.38 ± 0.13 2.17 ± 0.16 2.52 ± 0.19
Comparing the transmission of red light at 633 nm
to that of NIR light at 830 nm in a human cadaveric
model, Jagdeo et al. observed that 830 nm had better
transmittance compared to 633 nm, and that occipi-
tal delivery allowed the highest amount of energy to
enter the brain, as shown in Table 1 [62]. Bungart et al.
investigated different wavelengths for transcranial
PBM and concluded that a combination of 660 nm
and 810 nm provided superior penetration compared
to a combination of 980 nm and 1064 nm [25].
Once the light penetrates through the skull, the
further depth of penetration is limited by the optical
properties of brain tissue. Table 2 shows some results
from Stolik et al.’s ex vivo, post mortem measure-
ments of the penetration depths of red and NIR light
directly in brain tissue (without extracranial applica-
tion), suggesting that light with longer wavelengths
will penetrate deeper into the tissue [63].
To investigate which wavelength within the tissue
optical window will penetrate the deepest and deliver
the highest dose, the values for the tissue absorp-
tion coefficients as well as the penetration depth were
extracted from [23 and 63] and extrapolated by use
of polynomial trend lines as shown in Fig. 3. While
Fig. 3 suggests that a wavelength between 700 nm and
830 nm is likely to have the most effective and also
the deepest delivery of light energy to areas inside the
brain, an article by Wu et al. claimed that illumination
with 730 nm appeared to be ineffective when used for
traumatic brain injury in mice [64]. They reasoned
that the CCO absorption spectrum has a minimum at
730 nm and they suggested to use a mix of 665 nm
and 810 nm instead, seeing as CCO has two distinct
absorption bands at these wavelengths.
Energy density and dose
Summing up the available body of research on
PBM to the brain, the application time should be
long enough to achieve a dose in the minimum effec-
tive range between 5–10 J/cm2 at the level of the
cortex, therefore, considering the exponential energy
decrease during transcranial application, energy den-
sities between 25–60 J/cm2 applied to the human
scalp are suggested. With 250 mW/cm2 continuous
wave light, this corresponds to a 4 min treatment,
using a 100 mW/cm2 continuous wave light would
increase the treatment time to 10 min. Pulsing with
alpha or gamma frequency might add additional ben-
efit to PBM against AD, and a 50% duty cycle would
necessitate a doubling of the treatment time to achieve
the same dose as with continuous wave light.
CONCLUSION
When comparing the specifications of PBM
devices used in the available literature, especially
wavelength and power density, a range of options
have already been tested. It can be summarized that
the optical window for deep tissue penetration sug-
gests the best results at wavelengths in the far red
and NIR range, e.g., at 660 nm and 810 nm. The
irradiation intensity of a suitable device for pho-
tobiomodulation therapy for AD needs to permit
delivery of a dose of up to 60 J/cm2 to the scalp
within a reasonable period of time while providing
a power density below the risk of thermal damage
(<250 mW/cm2). The survey of the available litera-
ture in this review supports the assumption that PBM
with the correct parameters could be useful in the
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Fig. 3. Using literature reports on the transmittance of near infrared light through the scalp and skull, as well as the penetration depth inside
the brain, mathematical trends were established in order to provide meaningful values for wavelengths that are not covered in the literature.
fight against AD. Study protocols suitable for large
placebo-controlled studies are now available and we
should be able to get significant results with repre-
sentative statistical power within a year. The time to
act is now—lest we forget.
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